Skip to main content

Tanguler Tolga's Form 4 filing

Alnylam Pharmaceuticals, Inc. (ALNY) · filed Sep 2, 2025

Accession no.
0001735276-25-000094
Filed
Sep 2, 2025
Trade date
Aug 29, 2025
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 6 non-derivative transactions. Open-market sales total $1.56M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Tanguler TolgaCIK 0001849458Officer (EVP, Chief Commercial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 29, 2025Common StockSSaleDisposed−195$445.53F2−$86,878.3529,271Direct
Aug 29, 2025Common StockSSaleDisposed−899$446.98F3−$401,835.0228,372Direct
Aug 29, 2025Common StockSSaleDisposed−1,289$448.05F4−$577,536.4527,083Direct
Aug 29, 2025Common StockSSaleDisposed−681$449.54F5−$306,136.7426,402Direct
Aug 29, 2025Common StockSSaleDisposed−266$451.52F6−$120,104.3226,136Direct
Aug 29, 2025Common StockSSaleDisposed−144$452.49F7−$65,158.5625,992Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $445.32 to $445.79. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Referenced by the price of 1 transaction in Table I.

F3

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $446.34 to $447.34. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Referenced by the price of 1 transaction in Table I.

F4

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $447.59 to $448.58. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Referenced by the price of 1 transaction in Table I.

F5

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $449.07 to $449.98. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Referenced by the price of 1 transaction in Table I.

F6

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $451.21 to $451.68. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Referenced by the price of 1 transaction in Table I.

F7

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $452.22 to $452.54. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)